YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu…
PASADENA, Calif., September 02, 2026--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that compan…
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As the month of August 2026 comes to a close, the broader stock market has exhibited a mix of late-summer consolidati…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
(RTTNews) - The following biotech stocks reached a 52-week high on August 12, 2026, driven up by key catalysts such as positive quarterly reports or promising results from clinical trials. BioVie Inc. (BIVI) BioVie is a clinical-stage biop…
Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.…
Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942 enrollment in XENITH-U…
-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- -- Ex-U.S. royalties remain unchanged -- PASADENA, Calif., July 29, 2026--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) ("Xencor"), a clinical-stage…
(RTTNews) - The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies. Xencor Inc. (XNCR) Xencor is a clini…
Xencor (XNCR) shares soared 16.9% in the last trading session to close at $17.47. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 18.3% gain over the past four…
[antibody in pink and red background selective focus 3d art] mirror-images/iStock via Getty Images Shares of Xencor (XNCR [https://seekingalpha.com/symbol/XNCR]) surged 17% on Friday, rising $2.52 to close at $17.47. The move came after th…
-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- PASADENA, Calif., July 17, 2026--(BUSI…
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. "Today's news…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Xencor's latest research update includes a US$1 increase in the stock's price target, while the model's fair value anchor of US$28.…
[Incyte headquarters in Wilmington, Delaware, USA] JHVEPhoto/iStock Editorial via Getty Images Incyte’s (INCY [https://seekingalpha.com/symbol/INCY]) immunotherapy Monjuvi, developed with Xencor (XNCR [https://seekingalpha.com/symbol/XNCR]…
Company Logo Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and rising investment, it’s vital…
Market forces rained on the parade of Xencor, Inc. (NASDAQ:XNCR) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the bus…
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26 start -- -- Plamotamab an…
-- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™ format optimizes bispecifics for treatment of aut…
Recognizing the Year's Most Significant Contributions to Canada's Innovative Healthcare Industry Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Bloom Burton & Co. ("Bloom Burton") is thrilled to announce the finalists for the 2026 Bloo…
Corcept Therapeutics (CORT) came out with a quarterly loss of $0.3 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quart…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.77%. June E-mini S&P futures (ESM26) fell -0.35%, and Ju…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.77%. June E-mini S&P futures (ESM26) fell -0.35%, and Ju…
The S&P 500 Index ($SPX) (SPY) today is down -0.16%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.50%. June E-mini S&P futures (ESM26) are down -0.174%, and June E-mini Nasd…
The S&P 500 Index ($SPX) (SPY) today is down -0.80%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.98%. June E-mini S&P futures (ESM26) are down -0.84%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.16%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.50%. June E-mini S&P futures (ESM26) are down -0.174%, and June E-mini Nasd…
The S&P 500 Index ($SPX) (SPY) today is down -0.80%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.98%. June E-mini S&P futures (ESM26) are down -0.84%, and June E-mini Nas…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Citi upgraded Ralph Lauren(RL) to Buy from N…
PASADENA, Calif., March 04, 2026--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Ph…
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $6.7 million in its fourth quarter. The Pasadena, California-based company said it had a loss of 9 cents per share. The results beat Wall St…
-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose in ccRCC in 2H26 --…